Evidence map›Paper›PMID 39402314›Full record

ArticleAnnals of hematology2024

Different prognosis according to treatment in patients with acute promyelocytic leukemia: How the outcome changed over time.

Emilia Scalzulli, Alessandro Costa, Ida Carmosino, Paolo Musiu, Maria Laura Bisegna, Maria Stefania De Propris, Claudia Ielo, Daniela Diverio, Clara Minotti, Saveria Capria and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Emilia ScalzulliHematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I- Sapienza University, Via Benevento 6, Rome, 00161, Italy.
Alessandro CostaHematology Unit, Department of Medical Sciences and Public Health, Businco Hospital, University of Cagliari, Cagliari, Sardegna, Italy.
Ida CarmosinoHematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I- Sapienza University, Via Benevento 6, Rome, 00161, Italy.
Paolo MusiuHematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I- Sapienza University, Via Benevento 6, Rome, 00161, Italy.
Maria Laura BisegnaHematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I- Sapienza University, Via Benevento 6, Rome, 00161, Italy.
Maria Stefania De ProprisHematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I- Sapienza University, Via Benevento 6, Rome, 00161, Italy.
Claudia IeloHematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I- Sapienza University, Via Benevento 6, Rome, 00161, Italy.
Daniela DiverioHematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I- Sapienza University, Via Benevento 6, Rome, 00161, Italy.
Clara MinottiHematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I- Sapienza University, Via Benevento 6, Rome, 00161, Italy.
Saveria CapriaHematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I- Sapienza University, Via Benevento 6, Rome, 00161, Italy.
Roberto LatagliataHematology Unit, Belcolle Hospital, Viterbo, Italy.
Maurizio MartelliHematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I- Sapienza University, Via Benevento 6, Rome, 00161, Italy.
Massimo BrecciaHematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I- Sapienza University, Via Benevento 6, Rome, 00161, Italy. breccia@bce.uniroma1.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A comprehensive analysis of 220 patients diagnosed with APL between 1993 and 2022 is here reported. Overall, 214 patients (97.2%) received induction therapy. Complete response (CR) was achieved in 97.4%, 100%, 100%, and 27% of patients treated with AIDA protocol, AIDA + Ara-C, ATRA + ATO, and ATRA monotherapy, respectively. Molecular complete response (CR

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLeukemia, Promyelocytic, AcuteAdolescentAdultAgedAged, 80 and overArsenic TrioxideCytarabineDisease-Free SurvivalFemaleHumansIdarubicinMaleMiddle AgedPrognosisRemission InductionArsenic TrioxideCytarabineIdarubicinTretinoinAcute promyelocytic leukemiaATOATRAEarly deathLong-term follow-upPrognostic factors

Identifiers

PMID39402314
PMCPMC11695447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.